TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue March 29, 2013